reztripeptid.hu / Articles / Checklist
Date Every Claim: A Checklist for Fast-Changing Peptide Facts
A practical checklist to date, version, and retire peptide claims before they become obsolete.
Attach a Date to Every Fact
Peptide regulations shift rapidly. A claim valid in January may be false by July. You must write the date next to every fact you record. This simple habit prevents the spread of outdated information. Without a date, a statement loses its context immediately.
Regulatory bodies update their lists frequently. The US FDA moved several peptides between safety categories in 2026. The World Anti-Doping Agency updates its prohibited list annually. These changes alter the legal status of substances overnight. Your notes must reflect the specific month and year of the rule.
Scientific evidence also evolves. A study published in 2025 might be retracted in 2026. The main mechanism paper for Dihexa faced retraction. Human trials for BPC-157 remain limited with very low certainty grades. Dating your sources helps you spot when new data invalidates old conclusions.
Use a standard format for your dates. Write '2026-04-22' instead of 'last April'. This removes ambiguity across time zones and calendars. It allows you to sort facts chronologically. You can quickly filter out information older than your current review window.
- Record the exact date of the regulation or study.
- Note the effective date if different from the announcement date.
- Include the version number for dynamic web pages or guidelines.
Record the Source Version
Not all sources carry equal weight. A vendor blog differs from a federal register entry. You must identify the specific document or database entry you used. Web pages change content without notice. A static snapshot or a direct link to the archive preserves the truth.
Official lists have version history. The FDA 503A bulk drug substance list changes as nominations are withdrawn. The WADA prohibited list has annual revisions. Citing the list name and the specific update cycle ensures accuracy. You avoid confusion between draft guidance and final rules.
Secondary sources often misinterpret primary data. News articles summarize complex regulatory votes. They may miss dissenting opinions or specific conditions. Always trace back to the original briefing document or the advisory committee vote count. The PCAC meeting records show split votes on peptides like BPC-157.
Document the retrieval method. Did you access the data via an API or a manual search? Automated pipelines might miss manual corrections. Human oversight catches nuances in legal text. Keep a log of how you found the information to verify the path later.
- Link to the primary regulatory document, not a summary.
- Note the publication date of the journal article or report.
- Record the specific committee vote count if applicable.
Mark Claims That Expire
Some facts have a built-in expiration date. Draft guidance periods end on specific deadlines. Comment windows close, turning proposals into policies. A temporary enforcement discretion policy may vanish once final rules arrive. You must flag these items for immediate review.
Regulatory shifts create hard deadlines. The US HHS issued interim policy for six peptides in late October 2026. This policy remains valid only until final rulemaking occurs. The comment period ended in mid-November 2026. Any claim relying on this interim status must be re-evaluated.
Clinical trial results can supersede previous assumptions. A Phase 3 failure invalidates earlier Phase 2 hopes. The TUDCA-ALS trial failed, leading to the withdrawal of the Relyvrio approval. Claims about efficacy must be retired when larger studies contradict them. Do not rely on small pilot studies when major trials exist.
Identify the trigger event for expiration. Is it a date, a vote, or a new publication? Set a reminder for the day after the deadline passes. Check if the temporary status became permanent or expired. Update your records to reflect the new reality immediately.
- Highlight draft guidance with an expiration date.
- Flag claims dependent on temporary enforcement discretion.
- Mark statements that rely on single small studies.
Schedule Regular Re-Checks
Set a calendar reminder for every active claim. Regulatory landscapes move too fast for annual reviews. A quarterly check aligns with typical agency cycles. The FDA and WADA update their lists at least once a year. More frequent checks catch interim changes.
Focus on high-volatility areas first. Peptides with pending PCAC votes need weekly attention. Substances with recent warning letters require immediate verification. The gray market vendors face constant FDA scrutiny. Their status changes as warning letters are issued.
Use automated tools where possible. Alerts for specific keywords on regulatory websites save time. Monitor the Federal Register for new notices. Track the WADA list updates for athlete-related substances. Combine automation with manual verification for critical claims.
Review the entire chain of evidence during re-checks. A single retraction can collapse a whole argument. The withdrawal of the Dihexa mechanism paper changed its scientific standing. Ensure that all supporting studies still hold up. Discard claims that lose their foundational evidence.
- Set quarterly reminders for regulatory status checks.
- Monitor FDA warning letters and WADA list updates monthly.
- Re-evaluate claims when new large-scale trials publish.
Retire Outdated Statements Visibly
Do not delete old facts silently. Archiving preserves the history of your research. It shows how your understanding evolved. Future readers see the correction process. This transparency builds trust in your methodology.
Label retired claims clearly. Use tags like 'OBSOLETE' or 'RETRACTED'. Add a note explaining why the fact changed. Mention the new regulation or study that replaced it. This prevents accidental reuse of incorrect data.
Maintain a changelog for your knowledge base. Document every update with a timestamp. List the specific changes made to each entry. This creates an audit trail for your research process. It helps you defend your conclusions against criticism.
Share the retirement reason publicly if appropriate. Explain the regulatory shift or scientific correction. This educates others in the community. It reduces the spread of misinformation. Clear communication stops the cycle of outdated claims.
- Archive old entries instead of deleting them.
- Add a visible tag indicating the claim is outdated.
- Write a brief explanation for the retirement.
Key takeaways
- Always attach a specific date to every peptide claim to capture regulatory volatility.
- Verify the exact source version and document the retrieval method for accuracy.
- Flag temporary policies and draft guidance with their expiration dates.
- Schedule quarterly re-checks for high-volatility regulatory areas.
- Archive outdated statements with clear labels instead of deleting them.
Related questions
How often should I check peptide regulatory status?
Check high-volatility areas like FDA compounding lists and WADA prohibited substances monthly. Conduct a full review of your active claims quarterly. Major agencies typically update lists annually, but interim policies and warning letters can change weekly. Set calendar alerts for specific deadlines mentioned in draft guidance.
What if a study supporting my claim gets retracted?
Immediately retire the claim and label it as retracted. Note the retraction date and the reason provided by the journal. Replace the claim with updated findings from other studies if available. If no new evidence exists, mark the topic as having insufficient data. Do not continue to cite the retracted paper.
Does a change in FDA category mean a peptide is legal?
No. Moving a substance from Category 2 to a different status does not automatically make it legal. The FDA removal from Category 2 in April 2026 was due to withdrawn nominations, not new safety findings. Compounding remains restricted to single-API products under strict conditions. Always verify the final legal status with official sources.
AI-assisted: drafted with a language model from the author's research notes, then edited and checked before publication. Author: Zoltán Varga, AI visibility researcher and AI ecosystem architect, Budapest.
